Integer Holdings Corp

Integer Holdings Corp(ITGR)股票分析

$126.700

-0.025 (-0.02%)收盤時

Loading chart…
最高
126.790
開盤
126.740
成交量加權均價
126.71
成交量
724.44K
市值
3.84B
最低
126.630
成交金額
91.79M
企業價值/稅息折舊攤銷前利潤(TTM)
17.05

Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation.

AI 分析 of Integer Holdings Corp (ITGR)

持有

Integer Holdings Corp is currently a hold. The stock is trading at $126.70, very close to the acquisition price of $127, which limits upside potential. The RSI is at 71.16, indicating it is overbought, and the forward P/E ratio is 22.42, suggesting it may be fairly valued at this price point. The primary risk is the recent downgrade by analysts, which reflects concerns about future performance post-acquisition.

分析師評級(5)

-31.93% 下跌空間
持有
2 買進
3 持有
0 賣出
目前: 126.70
最低
75.00
平均
86.25
最高
95.00

Benchmark

2026-08-13

目標價

—

持有

Piper Sandler

2026-08-03

目標價

$127

中性

KeyBanc

2026-08-03

目標價

$127

Sector Weight

BofA

2026-08-03

目標價

—

No Rating

Freedom Capital

2026-07-22

目標價

$112

買進

估值指標

Integer Holdings Corp(ITGR)目前預期本益比為 22.42,5 年平均預期本益比為 18.69。

預期本益比

高估
5 年均值 P/E
18.69
目前P/E
22.42
高估
21.77
低估
15.61

預期 EV/EBITDA

嚴重高估
5 年均值 EV/EBITDA
12.84
目前EV/EBITDA
17.05
高估
14.49
低估
11.19

預期股價營收比

合理
5 年均值 P/S
1.90
目前P/S
2.23
高估
2.24
低估
1.56

Alphio AI 對 ITGR 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%ITGR

$140.04

情境價格

基

基準

基準 · 50%ITGR

$133.90

情境價格

悲

悲觀

悲觀 · 25%ITGR

$130.08

情境價格

持有 ITGR 的大戶

H

HBK Investments L.P.

+ 持有ITGR

+3.13%

3個月報酬率

H

Heartland Advisors, Inc.

+ 持有ITGR

+1.95%

3個月報酬率

N

Nomura Holdings, Inc.

+ 持有ITGR

-1.11%

3個月報酬率

事件時間軸

2026-09-30 (ET)

08:30:00

Integer Holdings Receives Early Termination of Antitrust Waiting Period

2026-08-04 (ET)

06:30:00

Freedom Capital Downgrades Integer to Hold, Price Target $127

2026-08-03 (ET)

17:00:00

U.S. Stocks Rise as Middle East Tensions Ease, Oil Prices Drop 5%

17:00:00

Oppenheimer Downgrades Integer to Perform

12:00:00

Amazon's Market Cap Surpasses $3 Trillion

資訊

ITGR 常見問題 —— 由 Alphio AI 解答

Integer Holdings Corporation is a medical device contract development and manufacturing company. The Company serves the cardiac rhythm management, neuromodulation, and cardio and vascular markets. Its brands include Greatbatch Medical and Lake Region Medical. The Company’s Cardio & Vascular product line offers a range of components, subassemblies, and finished devices used in interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology procedures. Its interventional cardiology portfolio is focused primarily on the design, development and manufacture of catheter and wire-based technologies intended to diagnose and treat cardiac disease. Its electrophysiology products include devices used by electrophysiologists and interventional cardiologists for the treatment of cardiac arrythmias, such as atrial fibrillation. It operates in the Healthcare sector (ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS industry).

Integer Holdings Corp is currently a hold. The stock is trading at $126.70, very close to the acquisition price of $127, which limits upside potential. The RSI is at 71.16, indicating it is overbought, and the forward P/E ratio is 22.42, suggesting it may be fairly valued at this price point. The primary risk is the recent downgrade by analysts, which reflects concerns about future performance post-acquisition.

5 analysts cover ITGR: 2 rate it Buy, 3 Hold and 0 Sell. The average price target is 86.25.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易